New CV data to add to alogliptin's safety allure?
This article was originally published in Scrip
Executive Summary
New subanalyses of findings from the large-scale EXAMINE outcomes study with Takeda's antidiabetic alogliptin have added to the cardiovascular safety profile of the DPP-4 inhibitor in patients at high cardiovascular risk and may help differentiate the product in a crowded segment.